COAGADEX
The first and only treatment specifically for Hereditary Factor X Deficiency
Therapies
Kedrion Biopharma’s line of plasma-derived therapies is broad and diverse. With products to treat or prevent many rare diseases and conditions from hemolytic disease of the fetus and newborn to immune deficiencies to hemophilia, Kedrion Biopharma offers a wide and expanding array of treatments and therapies.
browse by therapeutic area
Rare and ultra-rare diseases / Coagulation disorders
Immunology / Neurology
Critical care
Mother and child health
Rare and ultra-rare diseases / Coagulation disorders
Mother and child health
Latest news about our therapies
Discover our press releases, media resources, event information and stay updated on the latest news.
Nov 20, 2024
FDA Approves Kedrion’s Bolognana Facility for Production of First and Only Treatment for PLGD-1, Ryplazim®
Sep 12, 2024
Kedrion Biopharma’s Focus on Advancing Patient Care in Rare Disease to be Showcased at NBDF Conference 2024
COR.0010.USA.24